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MaOBJECTIVES The aim of this paper is to describe the feasibility of a novel transcatheter approach for mitral valve
replacement using only venous access.
BACKGROUND Failure of mitral valve prostheses necessitating reoperation can represent a high-risk clinical scenario.
Although repeat cardiac surgery remains the standard of care for most failed mitral valve operations, nascent trans-
catheter options are under development for patients at high or extremely risk of surgery. Most often, this is performed
via a transapical approach in the operating room, with associated risk of complications as well as extended length of
hospital stay.
METHODS We describe a case series of 4 consecutive patients at high risk of reoperation with degenerative mitral
prostheses (bioprosthetic valves or rings) who successfully underwent transvenous, transseptal mitral valve replacement
with a commercially available transcatheter heart valve.
RESULTS From April to May 2014, 4 consecutive patients underwent transvenous, transseptal mitral valve replace-
ment with a transcatheter heart valve. The mean age was 72  9.9 years, and the average Society of Thoracic
Surgeons risk score was 12.5  7.2%. All patients had severe, life-limiting dyspnea. The 4 procedures were successful
without intra- or post-procedural complications; echocardiography indicated a well-seated and functioning mitral
valve-in-valve or valve-in-ring. Patients were discharged within 2 days after valve replacement with marked
improvement in dyspnea.
CONCLUSIONS We describe an innovative technique of transcatheter mitral valve replacement. This case series
demonstrates the feasibility of transcatheter mitral valve replacement using only femoral venous access, with a marked
reduction in complications and length of hospital stay compared with transapical access or redo surgery.
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FIGURE 1 Pre-Procedural Planning With CT
Computed tomography (CT) scan demonstrating traditional
echocardiographic views of the heart in a patient with mitral
stenosis after placement of 28-mm Carpentier-Edwards Physio
ring (Edwards Lifesciences, Irvine, California) with an Alﬁeri
stitch. See accompanying Online Video 1.
AB BR E V I A T I O N S
AND ACRONYM S
TEE = transesophageal
echocardiography
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 6 , 2 0 1 5 Coylewright et al.
M A Y 2 0 1 5 : 8 5 0 – 7 Transseptal Mitral Valve Replacement
851of stay of 2 to 3 weeks; thus, innovative ways to care
for these patients are urgently needed (5,8).
Transapical access, an approach familiar to heart
teams well versed in transcatheter aortic valve
replacement, has been used for mitral valve in valve-
in-ring implantation but is associated with major
complications including bleeding in more than one-
fourth of patients, and a minimum of 1-week length
of hospital stay remains the rule (9–11). We, and others,
have performed transvenous, transseptal mitral valve
replacement with use of an apical rail via a small,
percutaneously placed sheath in the ventricular apex
or a venous-arterial loop exteriorized at the femoral
artery (12–14). However, even with closure devices,
percutaneous transapical access is associated with risk
of hemothorax (15). Isolated case reports and small
series describe mitral valve-in-valve or valve-in-ring
procedures via a transseptal route (13,16).
To overcome these challenges, simplify access for
transcatheter delivery, minimize procedural risk, and
accelerate patient recovery, we developed a novel
technique of valve-in-valve or valve-in-ring implan-
tation that requires only venous access. We present
a case series of patients at high risk of reopera-
tion with degenerative mitral prostheses who suc-
cessfully underwent transvenous, transseptal mitral
valve replacement with commercially available
transcatheter valves.
METHODS
This case series includes 4 consecutive patients who
underwent a mitral valve-in-valve or valve-in-ring
procedure via a transseptal approach without the
use of left ventricular apical access or a venous-
arterial rail for valve delivery. All procedures were
performed in the Earl H. Wood Cardiac Catheteriza-
tion Laboratory at Mayo Clinic in Rochester, Minne-
sota, from April to May 2014.
Procedural inclusion criteria included the presence
of a mitral bioprosthesis or a complete ring amenable
to placement of an appropriately sized SAPIEN pros-
thesis. Patients with incomplete rings were not
considered. All patients were evaluated by a cardio-
thoracic surgeon at the referring hospital and at our
institution and were deemed high or prohibitive risk
for reoperation. Patients were engaged in a shared
discussion of the therapeutic options including
medical therapy, transcatheter valve replacement, or
redo surgery. Patients were informed of the off-label
use of the SAPIEN valve (Retroﬂex 3, Edwards
Lifesciences, Irvine, California), and written informed
consent was obtained. Institutional review board
approval was obtained for this report.PROCEDURE. The procedures were per-
formed in a cardiac catheterization laboratory
equipped with biplane ﬂuoroscopic imaging.
Procedures were planned and performed by
clinicians from interventional cardiology,
cardiovascular surgery, echocardiography, pediatric
cardiology, and anesthesiology. Cardiac anatomy and
valve sizing was performed using multimodality im-
aging, including transthoracic echocardiography,
transesophageal echocardiography (TEE), and
computed tomography (Figure 1, Online Video 1).
Detailed analysis of the anatomy of the ring
or prosthetic valve, as well as conﬁrmation of
manufacturer-speciﬁed and -measured internal di-
ameters, was performed before the procedure
(Figure 2). Procedures were performed with general
anesthesia, and percutaneous femoral venous access
was obtained after deployment of 1 Perclose ProGlide
suture (Abbott Laboratories, Abbott Park, Illinois).
Contralateral femoral venous and arterial access was
obtained for ventricular pacing and emergency arte-
rial access for left ventricular support if needed.
Transseptal puncture was performed with a Brock-
enbrough needle through a Mullins 7-French dilator
(Medtronic, Inc., Minneapolis, Minnesota) under TEE
and biplane ﬂuoroscopic guidance. Care was taken to
use ﬂuoroscopic prosthetic valve landmarks to ensure
a smooth curve into the mitral valve inﬂow with
FIGURE 2 Pre-Procedural Planning With Ex Vivo Models
(A) A 26-mm Edwards SAPIEN valve and 28-mm Carpentier-Edwards Physio ring (Edwards Lifesciences, Irvine, California) shown side by side.
(B, C) A 26-mm Edwards SAPIEN valve within the 28-mm Carpentier-Edwards Physio ring.
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852optimal coaxial alignment. Most often, this led to a
posterior and subtly inferior transseptal puncture.
Unfractionated heparin was administered to
maintain activated clotting time levels longer than
300 s. An Inoue guidewire (0.025 mm, 175 cm, Toray
Industries, Inc., New York, New York) was placed
through the transseptal dilator into the left atrium
and the interatrial septum was dilated with a
14-F Inoue dilator. The venous sheath was then
upsized to an Edwards 22- or 24-F Retroﬂex 3
delivery sheath (Edwards Lifesciences). A medium-
curl Agilis steerable catheter (St. Jude Medical, Inc.,
St. Paul, Minnesota) was introduced into the left
atrium and ﬂexed and steered toward the mitral valve
inﬂow, which was crossed with a 0.035-inch stiff
Angled Glidewire (Terumo Medical Corp., Somerset,
New Jersey) through a diagnostic 125-cm, 6-F
multipurpose catheter. Once in the left ventricle,
the glidewire was exchanged for a Lunderquist wire
with a hand-formed, double left ventricular curve
and a subtle secondary anterior deﬂection. If the
Lunderquist would not track through the multipur-
pose catheter, the Agilis catheter was advanced
through the mitral prosthesis into the left ventricle
for greater support. The Agilis and multipurpose
catheters were then removed, leaving the Lunder-
quist wire in place. The interatrial septum was dilatedeither with a 21-F TandemHeart kit dilator (Cardiac
Assist, Inc., Pittsburgh, Pennsylvania) or an 8- to 10-
mm diameter noncompliant balloon.
An Edwards SAPIEN transcatheter aortic valve
(Edwards Lifesciences) was prepared and oriented for
antegrade valve delivery. When introducing the
delivery system, the marker “E” was placed down, so
that clockwise rotation of the steering handle ﬂexed
the device to the patient’s left, aiding valve delivery.
Balloon sizing or valvuloplasty was not performed.
The transcatheter valve was advanced into the mitral
prosthesis and carefully positioned straddling the
sewing ring (Figure 3). Under rapid pacing, the
transcatheter valve was slowly inﬂated and small
push or pull movements on the stiff Lunderquist were
used to make ﬁne adjustments.
After prosthesis deployment, the degree of regur-
gitation and resultant gradients were measured, the
delivery system removed and the resultant atrial
septal defect assessed with TEE. All atrial septal
defects in this series were small with slight left to
right shunting, and none were closed. Heparin was
reversed with protamine, and venous access was
closed via Perclose ProGlide suture system (Abbott
Laboratories) with light manual pressure applied for
5 min. Arterial access was closed with Perclose
ProGlide sutures or manual pressure.
FIGURE 3 Placement of THV Centered on Bioprosthetic Sewing Ring
Combined paravalvular leak closure and mitral valve in valve implantation. (A) Minimal ﬂuoroscopic markers on a 29-mm Mosaic mitral valve
(Medtronic, Minneapolis, Minnesota). Wire external to struts. (B) Following percutaneous paravalvular leak closure with 2 Amplatzer vascular
plug II devices (St. Jude Medical Inc., St. Paul, Minnesota), a 26-mm SAPIEN THV (Edwards Lifesciences, Irvine, California) was placed across
the sewing ring, with ﬂaring of the THV. (C) The 2 valves are shown ex vivo to demonstrate the basal sewing ring in relation to the struts.
AVPII ¼ Amplatzer vascular plug II; THV ¼ transcatheter heart valve.
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853RESULTS
BASELINE CHARACTERISTICS. From April to May
2014, 4 patients underwent transseptal, transcatheter
mitral valve replacement at our institution. Patient
characteristics are summarized in Table 1. The meanTABLE 1 Patient Characteristics
Patient #1 Patient
Age, yrs 72 59
Sex Female Femal
STS score, % 11.2 23
History of CABG No Yes
Ejection fraction, % 68 57
NYHA functional class III III-IV
Creatinine, mg/dl 0.9 Chronic dialysis
Other comorbidities
(all patients have severe
pulmonary hypertension)
PAD with previous
left iliac stent,
atrial ﬁbrillation,
COPD, frailty
Severe PAD, hist
aortofemoral
renal failure
(5 yrs), diabe
oxygen requi
CABG ¼ coronary artery bypass grafting; COPD ¼ chronic obstructive pulmonary disease;
of Thoracic Surgeons.age was 72  9.9 years and the average Society of
Thoracic Surgeons risk score was 12.5  7.2%. All
patients were women with multiple comorbidities,
including the presence of severe pulmonary hyper-
tension and some degree of right ventricular dys-
function. All patients had severe dyspnea on exertion#2 Patient #3 Patient #4
74 83
e Female Female
7.8 8.0
Yes No
64 65
III III
1.6 0.8
ory
bypass,
on dialysis
tes type 2,
rement
Diabetes, history of
pericarditis, atrial ﬁbrillation,
chronic renal insufﬁciency
Carcinoid, diabetes
NYHA ¼ New York Heart Association; PAD ¼ peripheral arterial disease; STS ¼ Society
TABLE 2 Valve and Procedural Characteristics
Patient #1 Patient #2 Patient #3 Patient #4
Type Hancock bioprosthesis
(Medtronic, Minneapolis,
Minnesota)
Carbomedics Annuloﬂex ring
(Sorin, Milan, Italy)
Carpentier-Edwards Physio
ring (Edwards Lifesciences,
Irvine, California)
Mosaic bioprosthesis
(Medtronic, Minneapolis,
Minnesota)
Size, mm 25 26 28 29
Manufacturer ID, mm 22.5 26 26.9 26
TEE ID, mm 21  21 19  18 15  24 20  22
CT ID, mm 22 18  17 17  27 19  23
Mode of failure Stenosis Stenosis Stenosis Prosthetic and periprosthetic
regurgitation
Prosthesis age, yrs (procedure
date)
11 (2003) 4 (2010) 5 (2009) 4 (2010)
Transcatheter valve used 23-mm SAPIEN* 23-mm SAPIEN 26-mm SAPIEN 26-mm SAPIEN
Pre-/post-TTE mitral gradient,
mm Hg
18/10 21/7 25/7 12/10
Left atrial pressure, pre
(A/V/mean mm Hg)
21/31/20 21/39/23 23/40/26 20/50/26
Left atrial pressure, post
(A/V/mean mm Hg)
25/43/27 20/32/20 18/23/20 21/38/23
Pulmonary artery pressure, pre
(systolic/diastolic) mm Hg
Not measured 71/25 76/30 52/22
Pulmonary artery pressure, post
(systolic/diastolic) mm Hg
Not measured 75/25 46/24 46/22
*Edwards Lifesciences, Irvine, California.
A ¼ A wave; CT ¼ computed tomography; ID ¼ inner diameter; TEE ¼ transesophageal echocardiography; TTE ¼ transthoracic echocardiography; V ¼ V-wave.
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854that limited quality of life. The indication for all
patients’ initial valve procedures was mitral regurgi-
tation due to degenerative mitral valve disease.
Previously implanted prostheses varied by size
(25 to 29 mm) and type (2 bioprosthetic valves and 2
annuloplasty rings). Concomitant procedures at theFIGURE 4 Coaxial Valve-in-Ring Placement With Transseptal Access
(A) Final ﬂuoroscopic appearance of a 26-mm Edwards SAPIEN valve in a
California) with a Lunderquist wire (Cook Medical, Bloomington, Indiana
selection of transseptal puncture location and curved stiff wire. See acctime of initial valve surgery included coronary artery
bypass grafting (n ¼ 2), left atrial appendage ligation
(n ¼ 2), and additional stitch placement (Alﬁeri stitch)
in both of the repairs (Table 2).
The mechanism of prosthetic dysfunction was
mitral stenosis in the majority of patients (n ¼ 3) with28-mm Carpentier-Edwards Physio ring (Edwards Lifesciences, Irvine,
) shown. (B) Coaxial valve-in-ring alignment facilitated by careful
ompanying Online Video 2.
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855prosthetic and periprosthetic leak leading to severe
mitral regurgitation in the fourth patient. Patients
presented a mean of 6  3.4 years after valve surgery
(range, 4 to 11 years).
PROCEDURAL OUTCOMES. Coaxial alignment of the
valve was obtained across the mitral annulus, aided
by the ﬂexion provided by the SAPIEN retroﬂex de-
livery system (Figure 4). In 3 of the 4 patients, the
valve deployed predictably. In patient 3, with history
of mitral valve repair including an Alﬁeri stitch, the
valve was canted until the suture gave way, and then
sat predictably for ﬁnal deployment (Online Video 2).
All patients had successful implantation of the valve
without complications; there was no malpositioning,
valve embolization, need for post-dilation, or need
for subsequent surgery. Successful reduction in
gradient and regurgitation was noted immediately by
TEE (Figure 5, Online Videos 3 and 4).
IN-HOSPITAL COURSE. Patients were extubated in
the cardiac catheterization laboratory and trans-
ferred to the general telemetry ﬂoor. The fol-
lowing morning, transthoracic echocardiography wasFIGURE 5 Pre- and Post-Procedural Imaging of Mitral Valve-in-Ring
(A) Three-dimensional transesophageal echocardiography demonstrates
Edwards SAPIEN valve (Edwards Lifesciences, Irvine, California). (B) Con
16 mm Hg to 3 mm Hg after deployment. See accompanying Online Vidperformed, and patients were discharged to home
shortly after. One patient with pre-existing dialysis
stayed an additional day to undergo dialysis before
traveling home. We tailored antiplatelet and anti-
coagulant therapy to each patient based on their
comorbidities.
FOLLOW-UP. All patients were alive and sym-
ptomatically improved at the time of last follow-up
(1 month post-procedure in 1 patient, 6 months
post-procedure in 3 patients). None had had recur-
rent hospitalizations for heart failure. Systematic
functional testing (e.g., 6-min walk test) was not
performed.
DISCUSSION
Failure of mitral valve prostheses in patients with
advanced age andmultiple comorbidities is a high-risk
clinical scenario with redo surgery associated with an
increased risk of operative mortality and extended
hospital stay (8). We previously developed a trans-
septal approach using the Melody valve (Medtronic)
with an apical rail (14). We present a case series ofthe geometric change in the annular shape after deployment of
tinuous wave Doppler shows a reduction in mitral valve gradient from
eos 3 and 4.
PERSPECTIVES
WHAT IS KNOWN? Mitral VIV implantation for a
failing bioprosthesis is an emerging and promising
therapy for patients at high surgical risk.
WHAT IS NEW? We describe a transseptal valve
implantation technique that eliminates the need for
transapical access or surgical incisions of any sort
and uses only venous access.
WHAT IS NEXT? The technique has the potential
to signiﬁcantly reduce the morbidity and mortality
of mitral VIV implantation; further clinical
research and comparative outcome studies are
needed.
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856patients at high risk of reoperation with degenerated
mitral bioprostheses who successfully underwent
transvenous, transseptal mitral valve-in-prosthesis
with minimal morbidity and mortality. The current
technique both simpliﬁes antegrade valve implan-
tation and avoids the complications associated with
transapical puncture. We believe that this technique
represents an improvement over the apical rail
technique and, with further reﬁnement, may lead
to a viable and generalizable technique for treating
elderly high-risk patients with mitral bioprosthetic
dysfunction. The steerable delivery system enabled
coaxial geometry for successful antegrade valve de-
livery (17). We use the current technique in all
cases as the primary delivery mode. Avoiding left
ventricular apical access allowed for ambulation on
the day of procedure and appropriateness for hos-
pital discharge the following day, a striking differ-
ence compared with previous reports. In a series
of 23 mitral valve-in-valve procedures performed
via the transapical route, one-fourth of patients
had a major bleeding complication, with a length
of hospital stay of 6 days (interquartile range: 5 to
8 days) (17). In a mixed case series that included
patients undergoing a transseptal approach (8 of 17
patients), the mean length of hospital stay was
10  4 days (range: 3 to 26 days) (13). A venous-only
approach provides a unique opportunity to avoid
potential complications of bleeding, apical injury,
and lung injury posed with thoracotomy, as well as
increased length of hospital stay due to pain and
recovery.
Important technical considerations include valve
sizing. Careful study of valve geometry pre-procedure
and of manufacturer’s speciﬁcations was critical to
procedural execution. Similarly, surgical expertise
with knowledge of various mitral valve repair tech-
niques was critical to procedural success and
reduced risk of embolization (18). We used the SA-
PIEN prosthesis, which is now no longer manufac-
tured. The next generation SAPIEN XT and SAPIEN 3
prostheses have a longer delivery nose cone and
require assembly in the inferior vena cava (with the
balloon withdrawn against the valve leaﬂet direction
of opening), potentially negative features for the
antegrade technique. Crossing of the mitral valve
with a wire may result in entanglement in chordae,
a risk that we minimized with careful TEE visuali-
zation. Use of a balloon-tip catheter to cross the
mitral valve may minimize this risk. If difﬁculty is
encountered in antegrade crossing of the mitral
valve, snaring the wire and exteriorizing out the
femoral artery may be considered, although we didnot have to do this in this small series. Care will need
to be taken to ensure coaxiality of the prosthesis
because the valve will tend to be canted toward the
left ventricular outﬂow tract using this technique.
This is particularly important with rings, in which the
landing zone is shorter and precise placement more
challenging. Two patients had had mitral valve repair
with an Alﬁeri stitch. We did not select which oriﬁce
to cannulate, and the stitch yielded easily in both
cases.
STUDY LIMITATIONS. This is a novel case series of
transvenous mitral VIV implantation in 4 patients.
While the technique herein has the potential to
limit procedural morbidity, further study is needed
in a larger patient cohort. This case series was
limited to mitral bioprosthesis and repairs with
complete rings.
CONCLUSIONS
Transcatheter mitral valve replacement using only
femoral venous access can be safe and feasible. Pa-
tients at high or extreme risk of surgery may beneﬁt
from the approach with resultant decreases in com-
plications and length of hospital stay compared with
traditional surgery or a transapical approach.
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